Clinical Trial

The Efficacy of Topical Formulation Containing Ciplukan (Physalis Angulata Linn.) on Psoriasis Vulgaris Lesions

Enrolling by Invitation Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated April 1, 2025 (before its estimated April 10, 2025 completion). Its status may not reflect the trial's current state.
Summary
Psoriasis vulgaris is a chronic inflammatory skin disease mediated by the immune system, with a complex pathogenesis that requires long-term therapy. Various inflammatory mediators that activate and are produced from the NF-κB signaling pathway play a role in the pathogenesis of psoriasis vulgaris. Topical corticosteroids are the first-line therapy for all severity levels of psoriasis vulgaris, possessing immunosuppressive, anti-inflammatory, and antimitotic effects. However, long-term use can lead to side effects such as atrophy, striae, telangiectasia, hypopigmentation, acneiform eruptions, perioral dermatitis, and hypertrichosis.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-13.
Trial Details
NCT Number NCT06887322
Lead Sponsor Universitas Padjadjaran
Conditions Psoriasis Vulgaris, Inflammation
Enrollment 40 participants
Start Date 2025-02-13
Primary Completion 2025-04-10 (estimated)
Study Completion 2025-04-10 (estimated)
Updated on ClinicalTrials.gov 2025-04-01